Weili Medical (603309.SH) intends to jointly invest with related parties to establish a subsidiary in Indonesia to invest in and construct a production base.

Zhitong Financial APP News, and Vilit Medical (603309.SH) announced that, in accordance with the company's overall strategic plan to improve the layout of the company's overseas production base and establish overseas product service supply capabilities, the company plans to establish an Indonesian subsidiary with a total investment of 500 billion Indonesian Rupiah (equivalent to approximately 20 million RMB) with its wholly-owned subsidiary Vilit Global Limited as the main contributor, along with Mr. Xiang Bin, the company's chairman and actual controller. The investment will be used for the establishment of a production base, including but not limited to leasing and renovating factory buildings, purchasing and installing machinery and equipment, company operations, qualification certifications, and providing initial working capital. Vilit Global Limited will contribute 475 billion Indonesian Rupiah and hold a 95% stake, while Xiang Bin will contribute 25 billion Indonesian Rupiah and hold a 5% stake. The full investment from the subsidiary is sourced from the company's own funds and does not involve the use of raised funds.